If you work in the biologics industry, you already know that the Biologics License Application (BLA) is one of the most complex regulatory submissions in the world. Governed by the Public Health Service Act Section 351 and the Federal Food, Drug, and Cosmetic Act, the BLA is the gateway to bringing biological products from monoclonal antibodies and vaccines to gene and cell therapies to the U.S. market.
But navigating the BLA process requires more than just filling out forms. It demands a deep understanding of eCTD structure, CMC data requirements, integration of nonclinical and clinical studies, FDA review dynamics, and post-approval lifecycle management.
That’s why we developed our Biologics License Application (BLA) Certification Program (https://www.gxptrainings.com/courses/biologics-license-application-bla-submission/) – a comprehensive, 15-module curriculum designed to equip regulatory professionals with the knowledge and skills to lead successful BLA submissions.
What Is a Biologics License Application (BLA)?
A BLA is the formal request submitted to the FDA for permission to introduce a biological product into interstate commerce. Under 21 CFR 601.2, the application must contain data derived from nonclinical laboratory and clinical studies demonstrating safety, purity, and potency – the three pillars of biologics licensing.
Products that require a BLA include:
- Monoclonal antibodies (e.g., Rituximab, Trastuzumab, Pembrolizumab)
- Vaccines (Influenza, MMR, HPV, COVID-19)
- Gene therapies (Luxturna, Zolgensma)
- Cell therapies (CAR-T therapies like Kymriah, Yescarta)
- Blood products (Albumin, IVIG, Factor VIII)
- Recombinant proteins (Epoetin alfa, Filgrastim)
Key distinction: Synthetic peptides of 40 or fewer amino acids follow the NDA pathway under the FD&C Act, not the BLA pathway.
Why the BLA Submission Process Is Unique
Unlike small-molecule drugs, biologics are process-dependent. Changing the manufacturing process can alter glycosylation profiles, aggregation levels, potency, and even immunogenicity risk. That’s why the FDA requires extensive CMC characterization and process validation for biologics.
The BLA submission covers:
- Regulatory foundation: PHS Act, FD&C Act, 21 CFR Parts 600, 601, 610, 210, 211
- eCTD submission: Modules 1 through 5 structure and content
- CMC: Drug substance, drug product, process validation, stability, viral safety
- Nonclinical studies: Pharmacology, toxicology, pharmacokinetics, immunogenicity
- Clinical studies: Phase 1-3 design, safety, efficacy, biostatistics
- FDA review process: Filing, mid-cycle, late-cycle, advisory committee
- Inspections: Pre-license, facility, inspection readiness
- Post-approval: Supplements, annual reports, post-marketing requirements, change control
- Special programs: Accelerated approval, breakthrough therapy, orphan designation, pediatric studies
Who Needs BLA Expertise?
The BLA submission process is a multidisciplinary effort that requires coordination across multiple functions. Our program is designed for professionals who work in or support the biological product industry, including:
- Regulatory Affairs Professionals
- CMC Scientists and Technical Writers
- Quality Assurance and Quality Control Personnel
- Manufacturing Personnel (bioprocess, fill/finish, quality operations)
- Clinical Development Teams (physicians, clinical scientists, project managers)
- Nonclinical Scientists (pharmacology, toxicology, pharmacokinetics)
- Pharmacovigilance Professionals
- Regulatory Project Managers
- Medical Writers
- Biotechnology Executives
- Regulatory Consultants
- Auditors and Inspectors
Whether you’re an early-career professional or an experienced regulatory affairs specialist, the curriculum is structured to meet you where you are and take you to the next level.
What You’ll Learn: 15 Modules of Comprehensive BLA Training
Our BLA Certification Program (https://www.gxptrainings.com/courses/biologics-license-application-bla-submission/) covers the complete regulatory framework governing biologics from initial discovery through post-approval lifecycle management.
Module 1: Foundations of Biologics License Applications
Learn the historical evolution of biological product regulation, statutory authorities under the PHS Act and FD&C Act, and the key CFR parts governing biologics.
Module 2: Product Development Lifecycle – Discovery to Post-Approval
Map the complete biological product lifecycle, identify critical decision points for BLA submission readiness, and develop integrated development timelines.
Module 3: Regulatory Framework – 21 CFR Parts 600, 601, 610, 210, and 211
Navigate the specific requirements for biologics licensing, cGMP applicability, human subject protection, and record retention.
Module 4: eCTD Framework – Module 1 Administrative Information
Master the required documents for Module 1, including Form FDA-356h, proposed labeling, financial disclosure forms, and user fee cover sheets.
Module 5: eCTD Module 2 – Summaries and Overviews
Write effective Quality Overall Summaries (QOS), Nonclinical and Clinical Overviews, and integrate data into the Integrated Summary of Safety (ISS) and Integrated Summary of Effectiveness (ISE).
Module 6: eCTD Module 3 – Quality (CMC) Overview
Understand the structure of Module 3, differentiate between Drug Substance (3.2.S) and Drug Product (3.2.P) sections, and identify critical quality attributes (CQAs) for biologics.
Module 7: Process Development and Validation
Learn Quality by Design (QbD), process qualification with three consecutive successful batches, and continued process verification (CPV).
Module 8: Analytical Methods and Validation
Identify the types of analytical methods required for biologics and understand method validation parameters per ICH Q2.
Module 9: Viral Safety and Adventitious Agents (ICH Q5A)
Implement testing for adventitious agents, design viral clearance studies, and interpret viral clearance validation results.
Module 10: Nonclinical Pharmacology and Toxicology
Design pharmacology and toxicology studies for biologics, determine the no-observed-adverse-effect level (NOAEL), and apply ICH S6 principles.
Module 11: Clinical Development and Efficacy
Design adequate and well-controlled efficacy trials, select appropriate primary and secondary endpoints, and interpret efficacy results.
Module 12: Clinical Safety and Integrated Summary of Safety (ISS)
Design a clinical safety database, categorize adverse events by seriousness and causality, and prepare an ISS.
Module 13: FDA Review Process and Advisory Committee
Describe the phases of the FDA review cycle, participate in mid-cycle and late-cycle meetings, and understand the role of advisory committees.
Module 14: Post-Approval Requirements and Change Management
Distinguish between post-marketing requirements (PMRs) and post-marketing commitments (PMCs), submit annual progress reports, and implement change control per 21 CFR 601.12.
Module 15: Special Programs and Global Comparisons
Identify eligibility criteria for accelerated approval, breakthrough therapy, and orphan designation, and compare US BLA requirements with EU and Japan.
Certification Requirements
To earn your certification, you must:
- Module Assessments (15): 10 multiple-choice questions per module, passing score 80%
- Capstone Project: BLA submission plan for a mock product, Pass/Fail
- Final Examination: 100 questions covering all modules, passing score 80%
Why Choose GxP Trainings?
At GxP Trainings, we specialize in regulatory compliance and quality assurance education for the life sciences industry. Our courses are designed by industry experts with real-world experience in FDA submissions, inspections, and post-approval compliance.
When you enroll in our BLA Certification Program (https://www.gxptrainings.com/courses/biologics-license-application-bla-submission/), you gain:
- Comprehensive curriculum covering every aspect of the BLA submission process
- Expert instruction from regulatory professionals with hands-on experience
- Practical skills you can apply immediately in your role
- Flexible learning designed for working professionals
- Certification that demonstrates your expertise to employers
Ready to Master the BLA Submission Process?
The biologics industry is growing rapidly, and the demand for regulatory professionals who understand the BLA submission process has never been higher. Whether you’re preparing for your first BLA submission or looking to deepen your expertise, our Biologics License Application (BLA) Certification Program (https://www.gxptrainings.com/courses/biologics-license-application-bla-submission/) gives you the knowledge and confidence to succeed.
Enroll Today: https://www.gxptrainings.com/courses/biologics-license-application-bla-submission/
Have questions about the program? Contact our team and we’ll be happy to help.
